What question did this study set out to answer?

To evaluate the effectiveness of evolocumab in reducing cardiovascular disease risk in individuals with no history of heart disease.

April 23, 2026

Evolocumab for Primary Prevention of Cardiovascular Disease

Key Points

To evaluate the effectiveness of evolocumab in reducing cardiovascular disease risk in individuals with no history of heart disease.
Randomized trial design
Participants had no previous cardiovascular events
Administration of evolocumab as a lipid-lowering intervention
Evolocumab significantly reduced LDL cholesterol levels (by X%) compared to placebo, p<0.05.
There was a notable decrease in cardiovascular events during the follow-up period.
Indicated a promising potential for primary prevention of cardiovascular disease.

Expert Takes9 quotes

1/9

“The VESALIUS-CV results support intensive LDL cholesterol-lowering, and one could argue maybe to a range of around 40 mg/dL, even in patients without a prior event. I highlight that number because the most recent guidelines for extreme-risk patients, which is not this population, suggest going below a target of 40 mg/dL.”

Erin Bohula, Cardiologist, Brigham and Women's HospitalBrigham and Women's Hospitalauto_pipelineView source

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

A Wed, study studied this question.

www.synapsesocial.com/papers/69ea386fc2ceeb8fbfae7e9b — DOI: https://doi.org/10.1056/nejmc2602103

Evolocumab for Primary Prevention of Cardiovascular Disease

Key Points

Expert Takes9 quotes

Citation Network

Connected Papers

Discussion

Cite this study

Expert Takes

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion